Tag Archives: drug development

Big Pharma's Second Life

Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle. The problem with overbearing project mangers on the sponsor side of […]
Posted in Biotech, People, R&D, Strategy, Supply Chain | Also tagged , , , , | Leave a comment

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. […]
Posted in Emerging Markets, IP, R&D, Strategy | Also tagged , | 1 Comment

Public Interest in Private Science: New Pathways to Measuring R&D Success

Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question:  are industry R&D priorities in synch with the changing burden of disease?
Posted in FDA, R&D | Also tagged , , | Leave a comment

Drug Innovation: Alive and Well at ASCO!

By John Otrompke. This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease. Improved results in progression-free survival in clinical trials suggest that many forms of cancer may soon take on a […]
Posted in Events, Guest Blog, R&D | Also tagged , | 1 Comment

NIH Director Speaks Out on the Institutes' New Remit

As the National Institutes for Health hits the headlines over its remit to help develop new medicines, Director Francis Collins talks to Pharm Exec about the new initiatives he sees as critical for innovation, industry and public health. Francis Collins devoted more than 15 years in the lab to deciphering the human genome. Ten years […]
Posted in FDA, Gene therapy, Guest Blog, healthcare, IP, leadership, R&D, Regulatory | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta